UBS Maintains Neutral on GoodRx Holdings, Lowers Price Target to $8.5
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Eric Sheridan maintains a Neutral rating on GoodRx Holdings (NASDAQ:GDRX) and lowers the price target from $9 to $8.5.
August 09, 2024 | 3:04 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
UBS analyst Eric Sheridan maintains a Neutral rating on GoodRx Holdings and lowers the price target from $9 to $8.5.
The lowered price target from $9 to $8.5 by UBS suggests a less optimistic outlook for GoodRx Holdings, which could lead to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100